* BioLife Solutions Inc BLFS.OQ reported a quarterly
adjusted
loss of 23 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -32 cents. The mean expectation of
eight analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -41 cents
to -10 cents per share.
* Revenue fell 15.9% to $31.73 million from a year ago;
analysts
expected $26.01 million.
* BioLife Solutions Inc's reported EPS for the quarter was a
loss
of 23 cents.
* The company reported a quarterly loss of $10.22 million.
* BioLife Solutions Inc shares had fallen by 3.3% this
quarter and
gained 10.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 17.6%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for BioLife Solutions
Inc is $21.50
This summary was machine generated from LSEG data May 9 at 10:41
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.28 -0.23 Beat
Dec. 31 2023 -0.34 -0.30 Beat
Sep. 30 2023 -0.37 -0.30 Beat
Jun. 30 2023 -0.20 -0.23 Missed